Hazards of the LA wildfires necessitate awareness that first responders and those central to the fires may be at risk for ...

Oncology nurses are familiar with the concept of financial toxicity, which refers to the significant financial burden cancer ...

Axel Stuart Merseburger, MD, PhD, explained that with TKIs like axitinib, it is necessary for oncology nurses to spend time ...

AUTX-703, a novel, oral KAT2A/B degrader, has received fast track designation for use in relapsed/refractory AML.

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose ...

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially ...

Experts discuss Robert’s journey with HER2-positive upper gastrointestinal (GI) cancer, highlighting key treatment approaches ...

Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease ...

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with chemotherapy in new findings.

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world ...

Immune checkpoint inhibitors for patients with cancer may be associated with an increased risk for psoriasis when compared ...

The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and ...